News
T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...
How could Trump's demands that drugmakers lower U.S. prices or face penalties impact pharma and biotech stocks? Seeking Alpha ...
The FDA has denied Stealth BioTherapeutics’ request to reconsider its complete response letter, leaving the fate of the biotech and its investigational treatment for an ultrarare genetic disease ...
How political red tape and a drug company’s thirst for profits limited the reach of a drug that experts believe could have ...
Developed by regenerative nanomedicine pioneer Samuel I. Stupp, the therapy harnesses molecular motion to reverse paralysis ...
Precision BioSciences Inc., a clinical-stage company developing gene editing therapies for diseases with high unmet need, has ...
10don MSN
Arcus Biosciences Inc. (NYSE:RCUS) is one of the biotech stocks to buy according to Wall Street analysts. On July 10, Arcus ...
SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...
Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...
The One Big Beautiful Bill Act takes a big step in the rare disease space by expanding the contours of the orphan drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results